Novacyt Aktie

Novacyt EPS

Indtjening pr. aktie (EPS) for Novacyt (ALNOV.PA) pr. 24. aug. 2026 er -0,59 GBP. I foregående år var Indtjening pr. aktie (EPS) -0,40 GBP — en ændring på 47,60 % (lavere).

EPS

-0,59GBP

YoY

47,60%

Senest opdateret:

Indtjening pr. aktie (EPS) for Novacyt er 2026 -0,59 GBP. Indtjening pr. aktie (EPS) for Novacyt var 2025 -0,40 GBP. Det falder dermed med 47,60% lavere sammenlignet med året før.

Novacyt EPS historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

EPS
Date
EPS
1. jan. 2020
1,94 GBP
1. jan. 2021
-0,14 GBP
1. jan. 2022
-0,36 GBP
1. jan. 2023
-0,40 GBP
1. jan. 2024
-0,59 GBP
1. jan. 2025 (e)
-0,15 GBP
1. jan. 2026 (e)
-0,13 GBP
1. jan. 2027 (e)
-0,07 GBP
Novacyt EPS historik
ÅREPSYoY
est-0,07GBP-44,00%
est-0,13GBP-19,01%
est-0,15GBP-73,80%
-0,59GBP+47,60%
-0,40GBP+9,96%
-0,36GBP+164,49%
-0,14GBP-107,09%
1,94GBP-1.644,83%
-0,13GBP+12,44%
-0,11GBP-46,66%
-0,21GBP-48,41%
-0,41GBP-80,17%
-2,05GBP+132,45%
-0,88GBP+158,27%
-0,34GBP+48,10%
-0,23GBP-94,92%
-4,53GBP-0,11%
-4,54GBP0,00%
-4,54GBP-34,38%
-6,92GBP
Access this data via the Eulerpool API

Novacyt Aktieanalyse

Hvad laver Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Novacyt aktie

Indtjening pr. aktie (EPS) for Novacyt er -0,59 GBP i 2026.

Indtjening pr. aktie (EPS) for Novacyt ændrede sig fra -0,40 GBP til -0,59 GBP, hvilket repræsenterer en ændring på 47,60 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Indtjening pr. aktie (EPS) Novacyt siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Indtjening pr. aktie måler den del af virksomhedens fortjeneste, der er allokeret til hver udestående aktie, og er en nøglekenntal til vurdering af en virksomheds rentabilitet pr. aktie.

EPS = Nettoindtjening / Udestående aktier

Access this data via the Eulerpool API

Resultatopgørelse — Novacyt

Alle nøgletal — Novacyt